EA200500232A1 - Способы диагностики и лечения преэклампсии или эклампсии - Google Patents
Способы диагностики и лечения преэклампсии или эклампсииInfo
- Publication number
- EA200500232A1 EA200500232A1 EA200500232A EA200500232A EA200500232A1 EA 200500232 A1 EA200500232 A1 EA 200500232A1 EA 200500232 A EA200500232 A EA 200500232A EA 200500232 A EA200500232 A EA 200500232A EA 200500232 A1 EA200500232 A1 EA 200500232A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- eclampsia
- preeclampsia
- methods
- treatment
- diagnostics
- Prior art date
Links
- 208000002296 eclampsia Diseases 0.000 title abstract 4
- 201000011461 pre-eclampsia Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010082093 Placenta Growth Factor Proteins 0.000 abstract 1
- 102100035194 Placenta growth factor Human genes 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
В настоящем изобретении раскрыты способы диагностики преэклампсии и эклампсии. Также в настоящем изобретении раскрыты способы лечения преэклампсии или эклампсии с использованием соединений, которые снижают уровни sFlt-1. Соединения, которые ингибируют связывание VEGF или PlGF с sFlt-1, также раскрыты в настоящем изобретении для лечения преэклампсии или эклампсии.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39748102P | 2002-07-19 | 2002-07-19 | |
US45179603P | 2003-03-03 | 2003-03-03 | |
US46739003P | 2003-05-02 | 2003-05-02 | |
PCT/US2003/022892 WO2004008946A2 (en) | 2002-07-19 | 2003-07-21 | Methods of diagnosing and treating pre-eclampsia or clamp |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200500232A1 true EA200500232A1 (ru) | 2005-12-29 |
Family
ID=30773520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500232A EA200500232A1 (ru) | 2002-07-19 | 2003-07-21 | Способы диагностики и лечения преэклампсии или эклампсии |
Country Status (19)
Country | Link |
---|---|
US (2) | US7407659B2 (ru) |
EP (3) | EP2305301B1 (ru) |
JP (2) | JP5650876B2 (ru) |
KR (1) | KR101215701B1 (ru) |
CN (1) | CN1777443B (ru) |
AP (1) | AP2005003230A0 (ru) |
AU (2) | AU2003265294B8 (ru) |
BR (1) | BRPI0312818B8 (ru) |
CA (2) | CA2922031C (ru) |
DK (3) | DK2305301T3 (ru) |
EA (1) | EA200500232A1 (ru) |
EC (1) | ECSP055608A (ru) |
ES (3) | ES2534294T3 (ru) |
HK (3) | HK1085368A1 (ru) |
IL (2) | IL166393A (ru) |
MX (1) | MXPA05000832A (ru) |
OA (1) | OA12890A (ru) |
PT (3) | PT2305301E (ru) |
WO (1) | WO2004008946A2 (ru) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0312818B8 (pt) * | 2002-07-19 | 2021-05-25 | Beth Israel Deaconess Medical Ct Inc | uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico |
US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
ATE394679T1 (de) * | 2002-11-16 | 2008-05-15 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
WO2005017192A2 (en) * | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
AU2005244167A1 (en) * | 2004-05-04 | 2005-11-24 | Beth Israel Deaconess Medical Center | Methods and compositions for treatment of preeclampsia |
US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
US20060067937A1 (en) * | 2004-09-24 | 2006-03-30 | Karumanchi S A | Methods of diagnosing and treating complications of pregnancy |
DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
DE602005023216D1 (de) * | 2004-12-15 | 2010-10-07 | Beth Israel Hospital | Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen |
ES2371084T3 (es) * | 2004-12-21 | 2011-12-27 | Yale University | Diagnóstico de la preeclampsia. |
US20060153835A1 (en) * | 2005-01-12 | 2006-07-13 | Smith Henry J | Treatment of pre-eclampsia in pregnant women using targeted apheresis |
CA2602963A1 (en) * | 2005-03-24 | 2006-09-28 | Beth Israel Deaconess Medical Center | Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy |
DE102005022047A1 (de) * | 2005-05-09 | 2006-11-30 | Dade Behring Marburg Gmbh | Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung |
JP2009501521A (ja) * | 2005-07-13 | 2009-01-22 | ベス イスラエル ディーコネス メディカル センター | 炎症応答を診断および処置する方法 |
US8329175B2 (en) | 2005-08-26 | 2012-12-11 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders |
US20070111326A1 (en) * | 2005-11-14 | 2007-05-17 | Abbott Laboratories | Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia |
US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
US20080071151A1 (en) * | 2006-06-30 | 2008-03-20 | Sogin David C | Method and Apparatus for Diagnosing Pre-eclampsia |
EP2046385B1 (en) | 2006-07-03 | 2015-03-25 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
EP1903339B1 (en) * | 2006-09-20 | 2010-08-04 | Roche Diagnostics GmbH | Natriuretic peptides and placental-growth factor/soluble VEGF-receptor discriminate cardiac dysfunction related to heart disease from a placenta-associated cardiac dysfunction in pregnant woman |
WO2008103202A2 (en) * | 2006-11-21 | 2008-08-28 | Beth Israel Deaconess Medical Center | Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications |
EP2099913B1 (en) * | 2006-12-20 | 2012-02-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Variants of vegfr and their use in the diagnosis and treatment of pregnancy associated medical conditions |
GB0703683D0 (en) * | 2007-02-26 | 2007-04-04 | Ark Therapeutics Ltd | The treatment of complications in pregnancy |
BRPI0907253A2 (pt) * | 2008-01-07 | 2015-07-14 | Ortho Clinical Diagnostics Inc | Determinação de complexo de sflt-1:fator angiogênico |
EP2245180B1 (en) * | 2008-01-25 | 2014-06-18 | PerkinElmer Health Sciences, Inc. | Methods for determining the risk of prenatal complications |
US9229009B2 (en) * | 2008-10-31 | 2016-01-05 | Yale University | Methods and kits for detecting misfolded proteins |
WO2010065437A1 (en) | 2008-12-03 | 2010-06-10 | Research Development Foundation | Modulation of olfml-3 mediated angiogenesis |
US8349325B2 (en) * | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
US20100247650A1 (en) * | 2009-03-31 | 2010-09-30 | Smith Henry J | Treatment for pre-eclampsia in pregnant women using targeted apheresis |
US8530150B2 (en) * | 2009-09-25 | 2013-09-10 | The University Of Bristol | Detection of risk of pre-eclampsia |
WO2011036429A1 (en) * | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
US9029627B2 (en) | 2010-03-04 | 2015-05-12 | Masaru Okabe | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
DE102010013555A1 (de) | 2010-03-31 | 2011-10-06 | Christian Hamm | Verwendung der Biomarker sFlt und PIGF in der Diagnose und Therapie der pulmonalen Hypertonie |
JP5959506B2 (ja) | 2010-05-14 | 2016-08-02 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | 妊娠合併症を治療するための体外デバイスおよび方法 |
WO2012010546A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
SG187013A1 (en) * | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
ES2683953T3 (es) * | 2011-02-07 | 2018-09-28 | Aggamin Llc | Procedimientos y sistemas para tratar o prevenir trastornos hipertensivos gestacionales |
EP2490027A1 (en) * | 2011-02-15 | 2012-08-22 | Roche Diagnostics GmbH | Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1 |
RU2460148C1 (ru) * | 2011-04-25 | 2012-08-27 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ коррекции нарушения микроциркуляции в плаценте при adma-подобной модели гестоза |
RU2466462C1 (ru) * | 2011-04-25 | 2012-11-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ коррекции нарушения микроциркуляции в плаценте рекомбинантным эритропоэтином при adma-подобной модели гестоза |
RU2462766C1 (ru) * | 2011-04-25 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ коррекции эндотелиальной дисфункции рекомбинантным эритропоэтином при adma-подобной модели гестоза |
RU2462765C1 (ru) * | 2011-04-25 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ коррекции эндотелиальной дисфункции дистантным прекондиционированием при adma-подобной модели гестоза |
DK2739310T3 (en) | 2011-08-05 | 2018-07-16 | Res Found Dev | Improved methods and compositions for modulating OLFML3-mediated angiogenesis |
EP2776839B1 (en) | 2011-11-09 | 2017-08-30 | Roche Diagnostics GmbH | Dynamic of sflt-1 or endoglin/plgf ratio as an indicator for imminent preeclampsia and/or hellp syndrome |
IN2014CN04326A (ru) * | 2011-12-15 | 2015-09-04 | Pronota Nv | |
RU2507595C2 (ru) * | 2012-03-07 | 2014-02-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ коррекции эндотелиальной дисфункции азитромицином при adma-подобной модели гестоза в эксперименте |
RU2507594C2 (ru) * | 2012-03-07 | 2014-02-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ коррекции эндотелиальной дисфункции при adma-подобной модели гестоза в эксперименте |
RU2483311C1 (ru) * | 2012-06-15 | 2013-05-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздравсоцразви | Способ диагностики преэклампсии у беременных с хронической артериальной гипертензией |
EP2706359A1 (en) | 2012-09-07 | 2014-03-12 | Roche Diagniostics GmbH | Means and methods applying sFlt-1/PlGF or Endoglin/PlGF ratio to rule-out onset of preeclampsia within a certain time period |
EP2867670B1 (en) | 2012-06-27 | 2018-05-30 | Roche Diagnostics GmbH | MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD |
KR101297886B1 (ko) * | 2012-10-02 | 2013-08-19 | 인제대학교 산학협력단 | 자간전증의 조기 진단 및 예후 평가 방법 |
US9803014B2 (en) | 2012-10-24 | 2017-10-31 | Research Development Foundation | JAM-C antibodies and methods for treatment of cancer |
WO2015027120A1 (en) | 2013-08-21 | 2015-02-26 | Jiang Jean X | Compositions and methods for targeting connexin hemichannels |
ES2685831T3 (es) | 2014-01-24 | 2018-10-11 | F. Hoffmann-La Roche Ag | Predicción del síndrome de HELLP postparto, de la eclampsia postparto, o de la preeclampsia postparto |
RU2543359C1 (ru) * | 2014-03-11 | 2015-02-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции эндотелиальной дисфункуии фармакологическим прекондиционированием никорандилом при adma-подобной модели гестоза в эксперименте |
JP6697394B2 (ja) | 2014-04-10 | 2020-05-20 | イェール ユニバーシティーYale University | 異常折り畳みタンパク質を検出するための方法および組成物 |
CN107636466B (zh) * | 2015-02-18 | 2020-07-21 | 阿斯顿大学 | 先兆子痫的诊断性测定和治疗 |
GB201504772D0 (en) | 2015-03-20 | 2015-05-06 | Univ Aston | Preeclampsia |
PT3277814T (pt) | 2015-04-03 | 2020-07-28 | Univ Massachusetts | Compostos de oligonucleótidos para visar marn de huntingtina |
RS62672B1 (sr) | 2015-04-03 | 2021-12-31 | Univ Massachusetts | Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja |
CN107683143A (zh) * | 2015-04-07 | 2018-02-09 | 夏尔人类遗传性治疗公司 | 治疗支气管肺发育不良的抗flt‑1抗体 |
CA2982815A1 (en) | 2015-04-07 | 2016-10-13 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
JP6675687B2 (ja) * | 2015-05-29 | 2020-04-01 | 国立大学法人名古屋大学 | 尿中VEGF−A165bを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体 |
FR3037657B1 (fr) * | 2015-06-22 | 2017-06-23 | Univ Rouen Centre Hospitalier | Methode de diagnostic des troubles causes par l'alcoolisation foetale |
EP3334499A4 (en) | 2015-08-14 | 2019-04-17 | University of Massachusetts | BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES |
WO2017096051A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
KR20180100122A (ko) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체 |
US10511462B2 (en) * | 2016-01-06 | 2019-12-17 | Apple Inc. | DC offset cancelation for wireless communications |
CA3011894A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
AU2017224122B2 (en) | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
BR112018015532A2 (pt) | 2016-02-29 | 2018-12-26 | Hoffmann La Roche | métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia |
CN109195991B (zh) | 2016-03-29 | 2023-10-31 | 斯特库比股份有限公司 | 对糖基化pd-l1特异的双重功能抗体及其使用方法 |
WO2017173091A1 (en) | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
KR101916652B1 (ko) * | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
EP3487883B1 (en) | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
CN107884570A (zh) * | 2016-09-29 | 2018-04-06 | 韦彦余 | 一种孕妇先兆子痫检测试剂盒 |
AU2018277545A1 (en) | 2017-05-31 | 2019-12-19 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 |
AU2018277838A1 (en) | 2017-05-31 | 2019-12-19 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof |
JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
EP3642341A4 (en) | 2017-06-23 | 2021-06-16 | University Of Massachusetts | TWO-DAY SELF-RELEASING SIRNA AND RELATED PROCEDURES |
JP2020533595A (ja) | 2017-09-13 | 2020-11-19 | プロジェニティ, インコーポレイテッド | 子癇前症バイオマーカならびに関連するシステムおよび方法 |
WO2019055825A1 (en) | 2017-09-15 | 2019-03-21 | The Regents Of The University Of California | INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER |
PL3758739T3 (pl) * | 2018-02-28 | 2024-09-16 | Pharming Intellectual Property B.V. | Leczenie i zapobieganie stanowi przedrzucawkowemu |
JP2021533762A (ja) | 2018-08-10 | 2021-12-09 | ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts | Snpを標的化する修飾オリゴヌクレオチド |
EP4010476A4 (en) | 2019-08-09 | 2023-12-27 | University Of Massachusetts | CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING SNPs |
JP2022549504A (ja) | 2019-09-26 | 2022-11-25 | エスティーキューブ アンド カンパニー | グリコシル化ctla-4に対して特異的な抗体およびその使用方法 |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
EP4107173A1 (en) | 2020-02-17 | 2022-12-28 | Board of Regents, The University of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
KR102435297B1 (ko) * | 2020-07-21 | 2022-08-22 | 부산대학교 산학협력단 | 임신중독증 조기진단용 바이오마커 조성물 및 이를 이용한 진단방법 |
AR126207A1 (es) | 2021-06-23 | 2023-09-27 | Univ Massachusetts | Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos |
AU2022405688A1 (en) | 2021-12-08 | 2024-06-06 | B.R.A.H.M.S Gmbh | Biomarkers for prognosis of early onset preeclampsia |
WO2024121392A1 (en) | 2022-12-08 | 2024-06-13 | B.R.A.H.M.S Gmbh | Multiple sflt-1 measurements for prognosis of early onset preeclampsia |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5238819A (en) * | 1988-12-14 | 1993-08-24 | The Regents Of The University Of California | Diagnostic assay for the detection of preeclampsia |
US5332671A (en) * | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5219739A (en) | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
US5543138A (en) * | 1994-03-10 | 1996-08-06 | Genetics Institute, Inc. | Methods of diagnosing and treating preeclampsia |
GB9512994D0 (en) * | 1995-06-26 | 1995-08-30 | Brf International | Method for quantitative measurement of an enzyme linked immunosorbent assay |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6399585B1 (en) | 1996-05-15 | 2002-06-04 | Janet E. Larson | In Utero treatment of CFTR-related deficiencies |
WO1998028006A1 (en) * | 1996-12-23 | 1998-07-02 | Cambridge University Technical Services Limited | Diagnosis and treatment of pathological pregnancies |
US20030114407A1 (en) | 2001-12-06 | 2003-06-19 | Monia Brett P. | Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression |
US6677300B1 (en) * | 1998-09-09 | 2004-01-13 | Scios, Inc. | Treatment of microvascular angiopathies |
EP1417971A3 (en) | 1998-09-09 | 2004-06-30 | Scios Inc. | Use of an angiogenic factor for the treatment of microvascular angiopathies |
US7030083B2 (en) | 1998-09-09 | 2006-04-18 | University Of Washington | Treatment of eclampsia and preeclampsia |
US6245577B1 (en) * | 1998-09-11 | 2001-06-12 | Midland Bioproducts Corporation | IgG antibody testing method |
EP1016726A1 (en) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
DK1309726T4 (en) | 2000-03-30 | 2019-01-28 | Whitehead Inst Biomedical Res | RNA Sequence-Specific Mediators of RNA Interference |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
GB0026823D0 (en) * | 2000-11-02 | 2000-12-20 | King S College London | Diagnosis of pre-eclampsia |
WO2002070535A1 (en) | 2001-03-01 | 2002-09-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of recql5 expression |
US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
BRPI0312818B8 (pt) * | 2002-07-19 | 2021-05-25 | Beth Israel Deaconess Medical Ct Inc | uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico |
WO2005017192A2 (en) * | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
ES2556164T3 (es) | 2003-09-23 | 2016-01-13 | The General Hospital Corporation | Cribado de la preeclampsia |
ES2371084T3 (es) | 2004-12-21 | 2011-12-27 | Yale University | Diagnóstico de la preeclampsia. |
US7335562B2 (en) * | 2005-10-24 | 2008-02-26 | Kabushiki Kaisha Toshiba | Method of manufacturing semiconductor device |
-
2003
- 2003-07-21 BR BRPI0312818A patent/BRPI0312818B8/pt not_active IP Right Cessation
- 2003-07-21 AU AU2003265294A patent/AU2003265294B8/en not_active Expired
- 2003-07-21 DK DK10180400T patent/DK2305301T3/en active
- 2003-07-21 WO PCT/US2003/022892 patent/WO2004008946A2/en active Application Filing
- 2003-07-21 CA CA2922031A patent/CA2922031C/en not_active Expired - Lifetime
- 2003-07-21 JP JP2005505542A patent/JP5650876B2/ja not_active Expired - Fee Related
- 2003-07-21 ES ES10180400.3T patent/ES2534294T3/es not_active Expired - Lifetime
- 2003-07-21 EA EA200500232A patent/EA200500232A1/ru unknown
- 2003-07-21 OA OA1200500018A patent/OA12890A/en unknown
- 2003-07-21 DK DK10180382T patent/DK2308507T3/da active
- 2003-07-21 MX MXPA05000832A patent/MXPA05000832A/es active IP Right Grant
- 2003-07-21 AP AP2005003230A patent/AP2005003230A0/xx unknown
- 2003-07-21 EP EP20100180400 patent/EP2305301B1/en not_active Expired - Lifetime
- 2003-07-21 PT PT101804003T patent/PT2305301E/pt unknown
- 2003-07-21 CA CA2496253A patent/CA2496253C/en not_active Expired - Lifetime
- 2003-07-21 EP EP20100180382 patent/EP2308507B1/en not_active Expired - Lifetime
- 2003-07-21 PT PT03765913T patent/PT1575416E/pt unknown
- 2003-07-21 DK DK03765913T patent/DK1575416T3/da active
- 2003-07-21 PT PT101803823T patent/PT2308507E/pt unknown
- 2003-07-21 US US10/624,809 patent/US7407659B2/en active Active
- 2003-07-21 KR KR1020057001052A patent/KR101215701B1/ko active IP Right Grant
- 2003-07-21 ES ES10180382.3T patent/ES2534926T3/es not_active Expired - Lifetime
- 2003-07-21 CN CN038221802A patent/CN1777443B/zh not_active Expired - Fee Related
- 2003-07-21 EP EP03765913.3A patent/EP1575416B1/en not_active Expired - Lifetime
- 2003-07-21 ES ES03765913T patent/ES2440651T3/es not_active Expired - Lifetime
-
2005
- 2005-01-19 IL IL166393A patent/IL166393A/en active IP Right Grant
- 2005-02-16 EC ECSP055608 patent/ECSP055608A/es unknown
-
2006
- 2006-03-20 HK HK06103543A patent/HK1085368A1/xx not_active IP Right Cessation
-
2008
- 2008-08-04 US US12/221,623 patent/US7947449B2/en not_active Expired - Fee Related
-
2009
- 2009-06-02 AU AU2009202176A patent/AU2009202176B2/en not_active Expired
-
2011
- 2011-10-06 HK HK11110529.6A patent/HK1156233A1/xx not_active IP Right Cessation
- 2011-10-13 HK HK11110874.7A patent/HK1156521A1/xx not_active IP Right Cessation
-
2014
- 2014-06-10 JP JP2014119588A patent/JP5973496B2/ja not_active Expired - Lifetime
- 2014-06-17 IL IL233205A patent/IL233205B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200500232A1 (ru) | Способы диагностики и лечения преэклампсии или эклампсии | |
DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
DK1682074T3 (da) | Præparater og fremgangsmåder til sund graviditet | |
NZ608431A (en) | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers | |
HK1069767A1 (en) | Methods for inhibiting ocular processes | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
TW200518755A (en) | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
ATE441418T1 (de) | Verwendung von treprostinil zur verbesserung der nierenfunktion | |
NO20056236L (no) | Behandling med anti-VEGF-antistoffer | |
BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
CY1110894T1 (el) | Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης | |
EA200700876A1 (ru) | Агенты, специфически связывающие ангиопоэтин-2 | |
NO20075304L (no) | Metode for avtagende forkalkning | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
DE60216300D1 (de) | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption | |
DE602004031095D1 (de) | Metallionenchelatoren und ihre therapeutische verwendung | |
HK1102626A1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
EA200601220A1 (ru) | Анти-trkc антитела-агонисты и способы их применения | |
ATE393917T1 (de) | Identifikation von therapeutische verbindungen. | |
EP1363528A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF HEART DISEASES | |
FR2873037B1 (fr) | Methodes et compositions pour le traitement de cancers | |
TNSN05015A1 (en) | Methods of diagnosing and treating pre-eclampsia or eclampsia | |
WO2003023048A3 (en) | METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) | |
WO2005046617A3 (en) | Compositions and methods for reducing microbial induced apoptosis |